Headlines
Bloomberg MarketsStocks Rise as Truce Prospects Weighed | Closing BellBloomberg MarketsUS to Make It Harder to Label Non-Banks ‘Too-Big-To-Fail’Bloomberg MarketsTrump Admin Allowing Defense Opportunities: Carlyle's FujiyamaBloomberg MarketsBlackstone's Chooses Cricket as First Sports M&ABloomberg MarketsBig Pipeline for Defense IPOs: JPMorgan's MarengoBloomberg MarketsSpaceX Maybe Largest US IPO, Iran War Reveals Gaps In Defense Spending | Bloomberg Deals 3/25/2026Bloomberg MarketsIran War Reveals Defense Spending GapsBloomberg MarketsWork to Do on Defense Supply Chain: Erin Price-WrightBloomberg MarketsIran’s Best Weapon Is the Strait of HormuzBloomberg MarketsMerck to Buy Terns for $6.7B to Grow in Blood CancersBloomberg MarketsBank of France Trims Growth Forecast, Sees Faster InflationBloomberg MarketsEnergy Uncertainty Delaying Some Deals: M&A Lawyer SpottswoodBloomberg MarketsGriffin's Citadel Posts Record $12 Billion Trading HaulBloomberg MarketsDolce & Gabbana Gears Up for Lender Talks as Debt Pressure RisesBloomberg MarketsBofA Starts Private Capital M&A Team to Focus on PE ExitsBloomberg MarketsStocks Rise as Truce Prospects Weighed | Closing BellBloomberg MarketsUS to Make It Harder to Label Non-Banks ‘Too-Big-To-Fail’Bloomberg MarketsTrump Admin Allowing Defense Opportunities: Carlyle's FujiyamaBloomberg MarketsBlackstone's Chooses Cricket as First Sports M&ABloomberg MarketsBig Pipeline for Defense IPOs: JPMorgan's MarengoBloomberg MarketsSpaceX Maybe Largest US IPO, Iran War Reveals Gaps In Defense Spending | Bloomberg Deals 3/25/2026Bloomberg MarketsIran War Reveals Defense Spending GapsBloomberg MarketsWork to Do on Defense Supply Chain: Erin Price-WrightBloomberg MarketsIran’s Best Weapon Is the Strait of HormuzBloomberg MarketsMerck to Buy Terns for $6.7B to Grow in Blood CancersBloomberg MarketsBank of France Trims Growth Forecast, Sees Faster InflationBloomberg MarketsEnergy Uncertainty Delaying Some Deals: M&A Lawyer SpottswoodBloomberg MarketsGriffin's Citadel Posts Record $12 Billion Trading HaulBloomberg MarketsDolce & Gabbana Gears Up for Lender Talks as Debt Pressure RisesBloomberg MarketsBofA Starts Private Capital M&A Team to Focus on PE Exits
Home/Bloomberg Markets
Back
MARKETS:
SPY+0.26%
DIA+0.23%
QQQ-0.14%
IWM+0.29%
GLD-0.40%
USO+1.64%
Bloomberg Marketsglobal

Merck to Buy Terns for $6.7B to Grow in Blood Cancers

Bloomberg Markets
Wednesday, March 25, 2026 at 7:01 PM
~4 min read

Original Report

Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Merck agreed to buy Terns Pharmaceuticals for $6.7 billion, giving the multinational company access to a promising new leukemia...

Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Merck agreed to buy Terns Pharmaceuticals for $6.7 billion, giving the multinational company access to a promising new leukemia treatment as it faces the patent expiration of its bestselling cancer drug. (Source: Bloomberg)

Glass House Analysis

Corporate decisions reverberate through local communities—a merger might mean headquarters relocating, a restructuring could eliminate jobs, and strategic shifts affect suppliers and service providers in countless towns. Behind quarterly earnings numbers are real employment decisions, investment choices, and community impacts that shape the economic landscape of regions across the country.

The implications extend beyond the immediate news cycle. Every economic development creates ripples that affect employment, prices, and opportunities in ways that may not be immediately visible but are deeply felt. By tracking these connections, we can better understand how the economy truly works—not as an abstract machine, but as a human system shaped by and shaping the lives of millions.

Enjoyed this analysis?

Get the Glass House Briefing every morning—market news that actually makes sense, delivered free to your inbox.

No spam. Unsubscribe anytime.

More Stories

Economic Context

S&P 500
+0.26%
Dow Jones
+0.23%
NASDAQ 100
-0.14%
Russell 2000
+0.29%